GNMSF (GNMSF) Stock Price & Analysis
GNMSF (GNMSF) fell 0.18% to USD 249 as of June 10, 2026 at 01:01 UTC, according to Nexqual real-time market data.
GNMSF last closed at USD 249.45; the session ranged USD 249–250 on volume of 178 shares. Market capitalization is $15.29B, with a 52-week range of USD 198.51–352 (PNK). Source: Nexqual, June 10, 2026 at 01:01 UTC.
Key Statistics (as of June 10, 2026 at 01:01 UTC)
| Price | USD 249 |
|---|---|
| Change | ▼ 0.18% (down) |
| Previous Close | USD 249.45 |
| Open | USD 250 |
| Day Range | USD 249 – 250 |
| 52-Week Range | USD 198.51 – 352 |
| Volume | 178 shares |
| Market Cap | $15.29B |
| Exchange | PNK |
Technical Analysis (GNMSF)
Nexqual's technical model rates GNMSF "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:01 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.74 (neutral) |
| vs SMA50 | Below (USD 264.52) |
| MACD | -6.21 (negative) |
Analyst Ratings (GNMSF)
Wall Street analysts rate GNMSF "None", per Nexqual as of June 10, 2026 at 01:01 UTC.
| Consensus Rating | None |
|---|
Earnings (GNMSF)
| Next Earnings Date | 2026-08-06 |
|---|---|
| Revenue Estimate | $6.95B |
Source: Nexqual, June 10, 2026 at 01:01 UTC.
Financials & Fundamentals (GNMSF)
| Total Revenue | $3.90B |
|---|---|
| Revenue Growth (YoY) | +25.30% |
| Gross Margin | +93.31% |
| Operating Margin | +25.11% |
| Profit Margin | +21.05% |
| ROE | +14.96% |
| Debt / Equity | 94.18 |
| Current Ratio | 2.18 |
| Total Cash | $1.52B |
| Total Debt | $5.35B |
| Free Cash Flow | $830.37M |
Source: Nexqual, June 10, 2026 at 01:01 UTC.
Financial Health Score (GNMSF)
Nexqual rates GNMSF's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 01:01 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 93%, operating 25% |
| Balance Sheet | Mixed — $1.52B cash vs $5.35B debt |
| Cash Flow | Mixed — FCF $830M, slim 3.5% margin |
| Efficiency | Mixed — ROE 15%, ROA 8.5% |
Ownership (GNMSF)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +40.62% |
| Shares Outstanding | 61.39M |
| Float | 60.64M |
Source: Nexqual, June 10, 2026 at 01:01 UTC.
Leadership (GNMSF)
GNMSF is led by Jan G.J. van de Winkel (age 64), Co-Founder, President & CEO, per Nexqual as of June 10, 2026 at 01:01 UTC.
| Co-Founder, President & CEO | Jan G.J. van de Winkel (age 64) |
|---|---|
| Executive VP & CFO | Anthony Pagano (age 47) |
| Executive VP & Chief Strategy Officer | Martine J. van Vugt (age 54) |
| Senior Director, Head of Development Business Partnership & Strategy and Director | Martin Schultz (age 50) |
| VP, Head of Antibody Research Materials & Director | Mijke Zachariasse (age 52) |
Major Backers & Investors (GNMSF)
Notable institutional backers of GNMSF include HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT., Bernstein Fund Inc-International Strategic Equities Portfolio, Fidelity, according to Nexqual as of June 10, 2026 at 01:01 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT. | 0.79% |
| Bernstein Fund Inc-International Strategic Equities Portfolio | 0.73% |
| Fidelity | 0.36% |
| Baird Funds Inc-Baird Chautauqua International Growth Fund | 0.35% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.63% |
| BlackRock | 1.04% |
Source: Nexqual, June 10, 2026 at 01:01 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CMXHF | CSL Ltd. | USD 66 | ▼ 6.44% |
| UCBJY | UCB S.A. | USD 151.74 | ▲ 1.47% |
| CSLLY | CSL Ltd. | USD 17.44 | ▲ 1.87% |
| DSKYF | Daiichi Sankyo Co., Ltd. | USD 14.96 | ▼ 2.09% |
| LZAGF | Lonza Group AG | USD 615.21 | ▼ 2.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:01 UTC. This page is informational and not investment advice.